Comparative Pharmacology
Head-to-head clinical analysis: BILDYOS versus EMPAGLIFLOZIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BILDYOS versus EMPAGLIFLOZIN.
BILDYOS vs EMPAGLIFLOZIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BILDYOS (pemigatinib) is a selective, potent, oral inhibitor of fibroblast growth factor receptor (FGFR) 1, 2, and 3. It binds to the ATP-binding pocket of FGFR kinases, inhibiting autophosphorylation and downstream signaling, thereby reducing proliferation and survival of tumor cells with FGFR alterations.
Sodium-glucose cotransporter 2 (SGLT2) inhibitor; reduces renal glucose reabsorption, increasing urinary glucose excretion.
Adults: 20 mg orally once daily.
10 mg orally once daily, with or without food; may increase to 25 mg once daily if eGFR ≥60 mL/min/1.73 m² and additional glycemic control needed.
None Documented
None Documented
Approximately 24 hours at steady state; supports once-daily dosing.
Clinical Note
moderateEmpagliflozin + Gatifloxacin
"Empagliflozin may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateEmpagliflozin + Rosoxacin
"Empagliflozin may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateEmpagliflozin + Levofloxacin
"Empagliflozin may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateEmpagliflozin + Trovafloxacin
"Empagliflozin may increase the hypoglycemic activities of Trovafloxacin."
Terminal elimination half-life is approximately 12.4 hours (range 10-18 h) in patients with T2DM; supports once-daily dosing.
Primarily biliary/fecal (unchanged drug and metabolites), approximately 90%; renal excretion accounts for less than 10% as unchanged drug and conjugates.
Renal (54% as unchanged drug) and fecal (41% as unchanged drug or metabolites); biliary excretion is minimal.
Category C
Category C
SGLT2 Inhibitor/Biguanide Combination Antidiabetic
SGLT2 Inhibitor